

Table S1. Co-expression of Rgs16::GFP with markers of endocrine cell types during pancreatic development.

	E8.5	E9.5	E10.5	E15.5
E-cadherin	-	-	-	3.5% 589 Rgs16 ⁺ ; 21 also E-cad ⁺
Sox9	90% 69 Rgs16 ⁺ ; 62 also Sox9 ⁺	58% 98 Rgs16 ⁺ ; 57 also Sox9 ⁺	11% 145 Rgs16 ⁺ ; 16 also Sox9 ⁺	5% 391 Rgs16 ⁺ ; 18 also Sox9 ⁺
Pdx1	-	-	-	53% 596 Rgs16 ⁺ ; 314 also Pdx1 ⁺
Ngn3	-	-	-	0% 469 Rgs16 ⁺ ; 0 also Ngn3 ⁺
Nkx6.1	-	-	-	52% 418 Rgs16 ⁺ ; 219 also Nkx6.1 ⁺
Synaptophysin	-	-	-	97% 387 Rgs16 ⁺ ; 375 also Synap ⁺
Glucagon	-	-	-	41% 119 Rgs16 ⁺ ; 49 also Glu ⁺
Insulin	-	-	-	52% 473 Rgs16 ⁺ ; 246 also Ins ⁺
Ki67	-	-	-	1.45% 2238 Rgs16 ⁺ ; 33 also Ki67 ⁺

Percentage co-expression of Rgs16::GFP with other endocrine markers, as a function of the total number of Rgs16::GFP⁺ cells.